# **FOSUN PHARMA**

## 复星医药

### 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

#### FORM OF PROXY FOR HOLDERS OF H SHARES FOR THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, 26 JUNE 2024

of				
being	the holder(s) of			overseas listed
foreig	n share(s) ("H Share(s)") <sup>(Note 3)</sup> of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company"), h	ereby appoint the	e company secretar	y of the Company
or				
of				
as my	/our proxy <sup>(Note 4)</sup> to vote and act for me/us at the annual general meeting (the "AGM") of the Company to b	e held Wednesda	y, 26 June 2024 at	1:30 p.m. at Sky
	he Boutique Hotel Shanghai, No. 358 Hong Xu Road, Shanghai, the PRC to vote for me/us as indicated below. have the same meanings as those defined in the circular of the Company dated 24 May 2024 (the "Circular").	Unless otherwise	stated, capitalized	terms used herein
	tick or insert the number of H Shares in the appropriate boxes to indicate how you wish your vote(s) to be cas	t on a poll (Note 5,	1	
ricase		For <sup>(Note 5)</sup>	Against <sup>(Note 5)</sup>	Abstain <sup>(Note 5)</sup>
1.	ORDINARY RESOLUTIONS  To consider and conveys the convey report of the Crown for the year 2022	ror	Against	Abstain
2.	To consider and approve the annual report of the Group for the year 2023.			
3.	To consider and approve the work report of the Board for the year 2023.			
4.	To consider and approve the work report of the Supervisory Committee for the year 2023.			
5.	To consider and approve the final accounts report of the Group for the year 2023.			
6.	To consider and approve the profit distribution proposal of the Company for the year 2023.			
0.	To consider and approve the re-appointment of Ernst & Young Hua Ming LLP as the PRC financial report and internal control report auditors of the Company for the year 2024 and re-appointment of Ernst & Young			
	as international financial report auditors of the Company for the year 2024 and the passing of remuneration			
	packages for the PRC and international auditors for the year 2023.			
7.	To consider and approve the appraisal results and remunerations of Directors for 2023.			
8.	To consider and approve the appraisal program of Directors for 2024.			
9.	To consider and approve the renewed and additional entrusted loans/borrowings quota of the Group.			
10	To consider and approve the additional total credit applications of the Company.			
11.	To consider and approve the authorisation of the management to dispose of the shares of the listed companies held by the Group.			
12.	To consider and approve the mandate to issue interbank market debt financing instruments.			
13.	To consider and approve the amendments to the Management System for Proceeds of the Company.			
14.	To consider and approve the amendments to the Related Party Transaction Management System of the Company.			
15	To consider and approve the provision of loan to Fosun Kite (a joint venture) in proportion to equity interest.			
	SPECIAL RESOLUTIONS	For <sup>(Note 5)</sup>	Against <sup>(Note 5)</sup>	Abstain <sup>(Note 5)</sup>
16.	To consider and approve the renewed and additional guarantee quota of the Group.			
17.	To consider and, if thought fit, approve the proposed grant of general mandate to issue A Shares and/or H Shares.			
18.	To consider and, if thought fit, approve the proposed grant of general mandate to repurchase H Shares.			
19.	To consider and, if thought fit, approve the proposed grant of general mandate to repurchase A Shares.			
20.	To consider and approve amendments to the Articles of Association and its Appendices.			
Signed	d thisday of2024 Signatur	re(s) <sup>(Note 6)</sup> :		
Notes:				
1.	IMPORTANT: You should first review the Circular carefully before filling in this proxy form.			

I/We (Note 2)

- IMPORTANT: You should first review the Circular carefully before filling in this proxy form.

  Full name(s) and address(es) (as shown in the register of members for H Shares) to be inserted in BLOCK CAPITALS.

  Please insert the number of H Shares registered in your name(s). If on number is inserted, this form of proxy will be deemed to relate to all the H Shares registered in your name(s).

  If any proxy other than company secretary of the Company is preferred, please strike out the words "the company secretary of the Company or" and insert the name and address of the proxy desired in the space provided. An H Shares in respect of which each such proxy is so appointed. Any alteration made to this form of proxy meed not be a member of the Company. If more than one proxy is so appointed, the appointment shall specify the number of H Shares in respect of which each such proxy is so appointed. Any alteration made to this form of proxy must be initialled by the person who signs it.

  IMPORTANT: If you wish to vote for any resolution, tick in the box marked "For". If you wish to vote against any resolution, tick in the box marked "Against". If you wish to abstain from voting on any resolution, tick in the box marked "Abstain". Any abstain vote at the AGM shall be disregarded as voting rights for the purpose of calculating the result of that resolution, but will be counted in the total number of voting shares. If you wish to vote only part of the H Shares in respect of which the proxy is so appointed, please state the exact number of H Shares in lieu of a tick in the relevant box. A tick in the relevant box indicates that the votes attached to all the H Shares to which this form relates will be cast accordingly. Unless you have indicated otherwise in this form, your proxy will also be entitled to vote at his discretion on any resolution properly put to the AGM other than those referred to in the notice convening the AGM.

  In case of joint holders, the vote of the joint holder whose name stands first in the register of mem

- \* for identification purposes only